KEGG   DRUG: RanibizumabHelp
Entry
D05697                      Drug                                   

Name
Ranibizumab (USAN/INN);
Ranibizumab (genetical recombination) (JAN);
Lucentis (TN)
Product
Formula
C2158H3282N562O681S12
Exact mass
48349.6111
Mol weight
48379.2865
Remark
Therapeutic category: 1319
ATC code: S01LA04
Product: D05697<JP/US>
Efficacy
Angiogenesis inhibitor, Anti-VEGF antibody
  Disease
Age-related macular degeneration [DS:H00821]
Macular edema following retinal vein occlusion [DS:H01651]
Diabetic retinopathy [DS:H01457]
Comment
Monoclonal antibody
Target
VEGFA [HSA:7422] [KO:K05448]
  Pathway
hsa04060  Cytokine-cytokine receptor interaction
hsa04370  VEGF signaling pathway
Brite
Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
 S SENSORY ORGANS
  S01 OPHTHALMOLOGICALS
   S01L OCULAR VASCULAR DISORDER AGENTS
    S01LA Antineovascularisation agents
     S01LA04 Ranibizumab
      D05697  Ranibizumab (USAN/INN) <JP/US>
Therapeutic category of drugs in Japan [BR:br08301]
 1  Agents affecting nervous system and sensory organs
  13  Agents affecting sensory organs
   131  Ophthalmic agents
    1319  Others
     D05697  Ranibizumab (USAN/INN); Ranibizumab (genetical recombination) (JAN)
Target-based classification of drugs [BR:br08310]
 Cytokines and receptors
  Cytokines
   Growth factors (RTK-binding)
    VEGFA
     D05697  Ranibizumab (USAN/INN) <JP/US>
New drug approvals in the USA [br08319.html]
 New Molecular Entity and New Therapeutic Biological Product Approvals
  D05697
New drug approvals in Europe [br08329.html]
 European public assessment reports (EPAR) authorised medicine
  D05697
New drug approvals in Japan [br08318.html]
 Drugs with new active ingredients
  D05697
New drug approvals in the USA, Europe and Japan [br08328.html]
 Approval dates by FDA, EMA and PMDA
  D05697
BRITE hierarchy
Other DBs
CAS: 347396-82-1
PubChem: 47207358
DrugBank: DB01270
NIKKAJI: J2.229.654J

» Japanese version   » Back

DBGET integrated database retrieval system